Research

Previously on May 31, 2024, the Superior Court of Delaware issued an Order Denying the Defendants' Motion to Dismiss the General Causation Experts in the Case of: "In Re: Zantac Ranitidine Products Liability" (Case Number N22C-09-101 ZAN in the Delaware Superior Court). Following that Denial, the Defendants filed a Motion for Certification of Interlocutory Appeal.  Today (July 1, […]

Yesterday (July 1, 2024) in after-market hours, it appears that the FDA has now approved eVenus' Generic Exparel. We currently believe that this news may be Negative for the share-price of Pacira BioSciences, Inc. (PCRX). Please see the following link for more details: Drugs@FDA: FDA-Approved Drugs Sincerely, Justin Wilcox, Senior Research Analyst MDC Financial Research, […]

Attached as a PDF file is MDC's "Event-Driven Legal℠" Weekly Report beginning July 2, 2024.  This Report summarizes near-term legal events and our thoughts on their potential as share-price catalysts for the indicated companies.  The Weekly Report also contains a listing of “At Any Time” events that we believe may be impactful to the share-price of the involved companies.   Please contact us for any additional information you would like to receive regarding […]